P3‐055: SYSTEMS BIOLOGY PLATFORM TO ENABLE NEUROINFLAMMATORY TARGET ID, VALIDATION, AND PATIENT SELECTION FOR DISEASE‐MODIFYING ALZHEIMER'S DISEASE THERAPEUTICS. (1st July 2019)